Can I Take Folate with Wegovy? A Women's Health Guide to Semaglutide and Folic Acid

The short answer: can you take folate with Wegovy?

Yes. No documented pharmacokinetic or pharmacodynamic drug-supplement interaction exists between semaglutide 2.4 mg (Wegovy) and folate in any form. The two do not compete for the same enzymes, transporters, or receptor pathways.

The nuance is in the biology around them. Semaglutide slows gastric emptying by acting on GLP-1 receptors in the gut and central nervous system, and slower gastric transit can reduce the rate at which water-soluble vitamins, including folate, are absorbed. This is a clinically meaningful concern mostly in women who are already at risk for folate deficiency: those with MTHFR gene variants, those who are or plan to become pregnant, those taking anticonvulsants, and those with significant Wegovy-induced nausea who are eating very little.

The sections below explain the mechanism in plain terms, walk through each life stage where the picture changes, and give you specific numbers to bring to your clinician.

How Wegovy affects your gut and why that matters for folate absorption

GLP-1 receptor agonists slow the stomach on purpose

Semaglutide activates GLP-1 receptors in the stomach, small intestine, and brainstem. One result is delayed gastric emptying, which contributes meaningfully to the satiety and weight-loss effect seen in the STEP 1 trial, where participants on semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks versus 2.4% on placebo.

Slower gastric emptying means nutrients spend more time waiting to reach the small intestine, where most absorption happens. For fat-soluble vitamins, this matters less. For water-soluble vitamins like folate, the rate of intestinal transit influences how much is taken up by the folate-specific transporters (primarily the reduced folate carrier, RFC1, and proton-coupled folate transporter, PCFT) in the proximal jejunum.

Does this cause clinical folate deficiency in practice?

Semaglutide trials were not designed to track micronutrient status as a primary endpoint, and no large randomized controlled trial has reported folate deficiency as a significant adverse event in Wegovy users. That is an honest evidence gap. What we know from bariatric surgery literature, where gastric transit is far more dramatically altered, is that folate deficiency is a recognized post-operative complication requiring supplementation, as noted in ASMBS and ACOG guidance on pregnancy after bariatric surgery.

Wegovy does not alter anatomy the way surgery does. The functional slowing is real but modest. For most women eating a balanced diet and taking a daily supplement, Wegovy-induced folate depletion is unlikely to be clinically significant. For women in any of the higher-risk groups described below, proactive monitoring makes sense.

Nausea, food aversion, and secondary micronutrient gaps

Up to 44% of women in the STEP 1 trial reported nausea, and significant nausea often reduces overall food intake and supplement adherence. A woman who stops taking her prenatal vitamin because it makes nausea worse, or who eats fewer folate-rich foods like dark leafy greens and legumes, is at greater risk for deficiency than one whose only variable is semaglutide's pharmacology.

MTHFR gene variants and why they change everything about "folate"

The folic acid vs. Methylfolate distinction

"Folate" is an umbrella term. Folic acid is the synthetic oxidized form used in most supplements and fortified foods. To be used by your cells, it must be converted to 5-methyltetrahydrofolate (5-MTHF), the biologically active form, via the enzyme MTHFR (methylenetetrahydrofolate reductase).

Roughly 10 to 15% of people of Northern European descent carry two copies of the MTHFR C677T variant, and population studies estimate that up to 40% of the US population carries at least one copy. Women with two copies (homozygous C677T) can have MTHFR enzyme activity reduced by 70%, meaning standard folic acid supplements may not raise their active folate levels adequately.

What this means for a woman on Wegovy

Here is a practical framework for thinking about folate form on semaglutide, organized by MTHFR status and life stage:

| Profile | Recommended folate form | Suggested daily dose | |---|---|---| | No known MTHFR variant, not pregnant, low GI side effects | Folic acid | 400 mcg | | MTHFR C677T heterozygous, not pregnant | Methylfolate (5-MTHF) | 400 to 800 mcg | | MTHFR C677T homozygous, not pregnant | Methylfolate (5-MTHF) | 800 to 1,000 mcg | | Reproductive age, sexually active, no contraception | Methylfolate or folic acid | 400 to 800 mcg | | Actively trying to conceive | Methylfolate preferred | 800 to 1,000 mcg (discuss with OB-GYN) | | On anticonvulsants (valproate, phenytoin, carbamazepine) | Methylfolate or high-dose folic acid | As directed by neurologist | | Significant Wegovy-induced nausea, poor oral intake | Methylfolate (better absorbed sublingually) | 800 mcg, separate from semaglutide dose day if possible |

If you have never been tested for MTHFR, you can ask your clinician for a cheek-swab or blood-based genetic test. It is not always covered by insurance, but the out-of-pocket cost is typically $20 to $80.

MTHFR, PCOS, and cardiovascular risk in women

Women with polycystic ovary syndrome (PCOS) are disproportionately represented among women seeking GLP-1 therapy for weight management. A 2020 meta-analysis in Fertility and Sterility found that MTHFR C677T was significantly associated with PCOS risk (OR 1.44, 95% CI 1.21 to 1.72). If you have PCOS and are on Wegovy, checking MTHFR status and optimizing folate form is a clinically reasonable step, not just supplementation trivia.

Elevated homocysteine, a downstream consequence of impaired methylation from MTHFR variants, is associated with increased cardiovascular risk in women, a concern that overlaps directly with the metabolic disease profile Wegovy treats.

Pregnancy, lactation, and contraception: the most important section for many women on Wegovy

Wegovy is contraindicated in pregnancy

This is not a gray zone. Semaglutide is classified by the FDA as pregnancy category X equivalent under the current labeling system: animal reproductive studies showed fetal harm at exposures below the clinical dose, and the Wegovy prescribing information states that it should be discontinued at least 2 months before a planned pregnancy. Two months is the washout window based on semaglutide's long half-life of approximately 1 week (roughly five half-lives to clearance).

If you are sexually active and not using reliable contraception, this must be discussed with your prescriber before starting Wegovy. ACOG recommends that all women of reproductive age on teratogenic medications use effective contraception, and ACOG Practice Bulletin 200 defines "highly effective" methods as those with typical-use failure rates below 1%, including IUDs, implants, and sterilization.

GLP-1 agonists may improve fertility in PCOS: a double-edged point

Here is a finding that surprises many women. Semaglutide and other GLP-1 agonists can restore ovulation in women with PCOS by reducing insulin resistance and androgen levels. A 2023 review in Obstetrics and Gynecology found that GLP-1 receptor agonists improved menstrual regularity and ovulation in anovulatory women with PCOS. This is good for long-term fertility goals, but it means a woman who thought she was "infertile" due to PCOS may become pregnant unexpectedly while on Wegovy. Contraception is not optional in this scenario.

Folate and pregnancy: start before you stop Wegovy

Because neural tube closure occurs between days 21 and 28 after conception, often before a woman knows she is pregnant, ACOG recommends starting folic acid or methylfolate supplementation at least one month before trying to conceive. The standard recommended dose is 400 to 800 mcg for women at average risk and 4 mg (4,000 mcg) for women with a prior pregnancy affected by a neural tube defect, as specified in ACOG Committee Opinion 804.

Practically, this means: if you are planning to conceive in the next year, start optimizing your folate status now, while you are still on Wegovy if applicable, and coordinate with your OB-GYN on the 2-month pre-conception Wegovy washout.

Lactation

Semaglutide has not been adequately studied in human lactation. Animal studies show transfer into milk, and given the molecular weight and half-life, transfer into human breast milk is plausible. The FDA label advises against use during breastfeeding. Folate, by contrast, is actively secreted into breast milk and supplementation during lactation is encouraged; the Dietary Reference Intake for folate during lactation is 500 mcg DFE (dietary folate equivalents) per day, according to the NIH Office of Dietary Supplements.

Life-stage guide: how folate needs change across a woman's reproductive lifespan on semaglutide

Reproductive years (ages 18 to 40, not currently pregnant)

Your primary concern is ensuring adequate folate for any potential pregnancy, plus covering baseline methylation needs. Take at least 400 mcg of folate daily, in methylfolate form if you have a known MTHFR variant. Time your supplement with a meal rather than on the morning of your semaglutide dose if nausea is significant on injection days (Wegovy is a once-weekly subcutaneous injection).

Trying to conceive

Stop Wegovy at least 2 months before you plan to conceive. Increase folate to 800 to 1,000 mcg methylfolate daily, starting immediately. Ask your clinician whether you need MTHFR testing and whether any other supplements (B12, choline) need adjustment. Weight management during a TTC period can shift to dietary approaches and, in some cases, shorter-acting GLP-1 agents that have faster washout, though none are formally approved for use in pregnancy.

Perimenopause (typically ages 40 to 52)

Ovulation becomes irregular, but pregnancy remains possible in perimenopause. Contraception is still recommended until 12 months after the final menstrual period. Folate at 400 to 800 mcg remains appropriate. There is emerging data suggesting adequate folate and B-vitamin status may support cardiovascular health and cognitive function during hormonal transition. Homocysteine tends to rise as estrogen falls, and a 2021 study in Menopause found that postmenopausal women with higher homocysteine had significantly greater risk of cognitive decline, a pathway where adequate folate may be protective.

Post-menopause

Pregnancy is no longer a concern, but folate remains relevant for one-carbon metabolism, DNA repair, and cardiovascular risk reduction. The 400 mcg standard recommendation applies. B12 co-supplementation becomes increasingly important after age 50 because gastric acid production declines and B12 absorption decreases; this matters because high-dose folate can mask B12 deficiency on standard blood tests, a risk specifically noted by the NIH Office of Dietary Supplements.

Anticonvulsants, folate, and Wegovy: a triad that needs specialist oversight

Some women take Wegovy and also use anticonvulsants for epilepsy, bipolar disorder, or chronic pain. Several anticonvulsants, including valproate, phenytoin, carbamazepine, and primidone, reduce serum folate levels through multiple mechanisms: they increase folate catabolism, reduce intestinal absorption, and compete for folate-binding proteins. A Cochrane review on folate and anticonvulsants confirmed that these drugs significantly reduce serum and RBC folate.

Layering semaglutide's gastric-emptying effects on top of anticonvulsant-induced folate depletion is a scenario where proactive monitoring, and possibly higher-dose methylfolate supplementation (up to 5 mg daily in some cases), is warranted. Do not adjust anticonvulsant folate dosing on your own; the interaction is complex and requires clinician guidance.

When to get your folate levels checked

Serum folate reflects recent intake. RBC folate reflects tissue stores over the past 90 to 120 days and is the more clinically useful test.

Consider asking for RBC folate testing if you:

• Have significant ongoing nausea or vomiting on Wegovy limiting your food intake
• Have a documented MTHFR C677T or A1298C variant
• Take any anticonvulsant medication
• Are planning pregnancy in the next 6 months
• Have a history of a prior pregnancy affected by a neural tube defect
• Drink alcohol regularly (alcohol increases folate excretion)
• Follow a diet low in leafy greens, legumes, and fortified grains

A serum folate below 2 ng/mL or an RBC folate below 140 ng/mL indicates deficiency. The NIH defines folate deficiency as an RBC folate concentration below 140 nmol/L (approximately 61.7 ng/mL) using updated reference ranges.

Practical timing: how to take folate on Wegovy

Wegovy is injected once weekly, subcutaneously, in the abdomen, thigh, or upper arm. It is not taken orally, so there is no direct competition between a folate tablet and semaglutide at the point of absorption.

The timing concern is indirect: nausea peaks in the first 24 to 48 hours after each injection, especially during dose escalation (the standard titration schedule runs 0.25 mg for 4 weeks, then 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at monthly intervals, per the prescribing information). If nausea on injection day consistently prevents you from taking your supplement, try:

1. Moving folate to the morning of the day before your injection, when you are likely feeling best.
2. Switching to a sublingual methylfolate, which dissolves under the tongue and does not require gastric absorption.
3. Taking folate with a small amount of food even when appetite is low.

None of these strategies require a dose-separation window in the pharmacological sense. This is about tolerability and consistency.

What to tell your doctor and what to ask

Bring these specific questions to your prescriber or dietitian:

• "Should I be tested for MTHFR before choosing between folic acid and methylfolate?"
• "Given my nausea pattern on Wegovy, what is the best time of week to take folate reliably?"
• "I am thinking about conceiving in the next 1 to 2 years. When should I stop Wegovy and what folate dose should I be on before I start trying?"
• "My serum folate was last checked [date]. Should I recheck RBC folate now that I am on semaglutide?"

If you take anticonvulsants, bring your neurologist into this conversation. The interaction between anticonvulsants, folate metabolism, and a GLP-1 agent that affects absorption is specific enough to warrant a coordinated plan.

Who folate supplementation on Wegovy is clearly appropriate for, and who needs a closer look

Women for whom folate supplementation alongside Wegovy is straightforward:

• Any woman of reproductive age (ACOG baseline recommendation)
• Women with PCOS using semaglutide for weight management and ovulation restoration
• Women in perimenopause or post-menopause taking a standard multivitamin containing 400 mcg folate

Women who need individualized assessment before settling on a dose and form:

• Women with confirmed or suspected MTHFR variants
• Women planning pregnancy within 2 years
• Women with significant GI side effects limiting supplement absorption
• Women on anticonvulsants
• Women with a prior neural-tube-defect pregnancy (who likely need 4 mg daily regardless)
• Women with celiac disease or inflammatory bowel disease, where baseline absorption is already compromised